chr5-149981315-TA-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000112.4(SLC26A2):βc.1724delAβ(p.Lys575fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000031 in 1,614,040 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ).
Frequency
Genomes: π 0.000039 ( 0 hom., cov: 32)
Exomes π: 0.000030 ( 0 hom. )
Consequence
SLC26A2
NM_000112.4 frameshift
NM_000112.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.760
Genes affected
SLC26A2 (HGNC:10994): (solute carrier family 26 member 2) The diastrophic dysplasia sulfate transporter is a transmembrane glycoprotein implicated in the pathogenesis of several human chondrodysplasias. It apparently is critical in cartilage for sulfation of proteoglycans and matrix organization. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 4 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 5-149981315-TA-T is Pathogenic according to our data. Variant chr5-149981315-TA-T is described in ClinVar as [Pathogenic]. Clinvar id is 4087.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-149981315-TA-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152218Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
152218
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000478 AC: 12AN: 251246Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135810
GnomAD3 exomes
AF:
AC:
12
AN:
251246
Hom.:
AF XY:
AC XY:
3
AN XY:
135810
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000301 AC: 44AN: 1461822Hom.: 0 Cov.: 35 AF XY: 0.0000385 AC XY: 28AN XY: 727206
GnomAD4 exome
AF:
AC:
44
AN:
1461822
Hom.:
Cov.:
35
AF XY:
AC XY:
28
AN XY:
727206
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152218Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74374
GnomAD4 genome
AF:
AC:
6
AN:
152218
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74374
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Achondrogenesis, type IB Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 1996 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Oct 15, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 29, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital | Nov 24, 2021 | The homozygous frameshift deletion variant c.1724delA has been previously reported as c.1751delA by Superti-Furga A et al in 1996 in a Dutch patient. The allele frequency-0.0048% in gnomAD (aggregated) database and 0.0058% in 1000g. Phenotype observed in the proband was cystic hygroma, generalized subcutaneous edema with skin thickening, hypoechogenic area and distorted fetal limbs. Achondrogensis IB is an autosomal recessive disorder. Based on the phenotypic observation and the available literature, we classify this variant as pathogenic. - |
Diastrophic dysplasia Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 1996 | - - |
Diastrophic dysplasia;C0265274:Achondrogenesis, type IB;C1847593:Multiple epiphyseal dysplasia type 4;C1850554:Atelosteogenesis type II Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 10, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2023 | This sequence change creates a premature translational stop signal (p.Lys575Serfs*10) in the SLC26A2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 165 amino acid(s) of the SLC26A2 protein. This variant is present in population databases (rs749382145, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with achondrogenesis, atelosteogenesis, and diastrophic dysplasia (PMID: 7923357, 8528239, 8571951; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 4087). For these reasons, this variant has been classified as Pathogenic. - |
Atelosteogenesis type II Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 1996 | - - |
Sulfate transporter-related osteochondrodysplasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 26, 2017 | Variant summary: The SLC26A2 c.1724delA (p.Lys575Serfs) variant results in a premature termination codon, predicted to cause a truncated or absent SLC26A2 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. This variant is absent in 121446 control chromosomes. This variant has been reported in multiple affected individuals and classified as pathogenic/likely pathogenic by clinical diagnostic laboratories and reputable databases. Taken together, this variant is classified as pathogenic. - |
Connective tissue disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | May 01, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at